Anti-Lipid Pharm Flashcards
MOA statins
HMG CoA reductase inhibitors –> lowers cholesterol levels –> increases LDL receptors –> increase LDL recycling
do statins decrease mortality in CAD patients
YES
adverse effects statins
hepatotoxicity
myopathy (especially when used with fibrates)
MOA bile acid resins
prevent intestinal reabsorption of bile acids –> liver then has to use cholesterol to make more
adverse effects bile acid resins
GI upset
decrease absorption of other drugs and fat soluble vitamins
MOA ezetimibe
prevents cholesterol absorption at small intestine brush border
adverse effects ezetimibe
rare increase in LFTs
diarrhea
MOA fibrates
upregulate LPL –> increases triglyceride clearance
also activates PPAR-a to induce HDL synthesis
adverse effects fibrates
myopathy (increased risk with statins)
cholesterol gallstones (via inhibition of choelsterol 7a-hydroxylase)
MOA niacin
inhibits lipolysis in adipose tissue
reduces VLDL synthesis
adverse effects niacin
flushed face
hyperglycemia
hyperuricemia
MOA PCSK9 inhibitors
inactivation of LDL-receptor degradation –> increases removal of LDL from bloodstream
adverse effects PCSK9 inhibitors
myalgias
delirium
dementia
MOA fish oil and marine omega-3 fatty acids
believed to decrease FFA delivery to liver and decrease activity of TG-synthesizing enzymes
Statins
- LDL levels
- HDL levels
- triglyceride levels
- LDL levels:
- HDL levels:
- triglyceride levels: